基本信息
浏览量:91
职业迁徙
个人简介
Research
Dr. Liotta has helped transform HIV/AIDS from a death sentence to a chronic infection in which patients can live active and productive lives. The Emory University Office of Technology Transfer estimates that about 95% of the people living with HIV/AIDS in the U.S., and many around the world, take or have taken one of the drugs co-invented by Dr. Liotta. He is most noted for his invention of emtricitabine and lamivudine, along with Drs. Raymond Schinazi and Woo-Baeg Choi. These two drugs are widely used as crucial components of anti-HIV combination therapies. They played instrumental roles in combating the HIV/AIDS epidemic in the U.S. and curbing the spread of HIV in other regions of the world. Emtricitabine, marketed under the name Emtriva, made possible the first-ever combination therapy for HIV/AIDS as a once-daily pill. It is a component of many combination therapies used to treat HIV/AIDS. Lamivudine, marketed under the name Epivir, is also a component of multiple combination therapies. Additionally, lamivudine became the first drug approved by the FDA to treat hepatitis B infections. Both emtricitabine and lamivudine are on the World Health Organization’s List of Essential Medicines.
In addition to antiviral therapeutics, Dr. Liotta has also made important contributions to other therapeutic fronts, such as oncology and neurological diseases. He co-discovered samuraciclib (formerly CT7001), a CDK7 inhibitor for treating hard-to-treat cancers. Samuraciclib is in Phase 2 clinical trials and has been fast-tracked by the FDA for use in two combination therapies to treat certain breast cancers. He also developed Q-122, an oral drug for controlling hot flashes in postmenopausal women, which has completed a Phase 2 clinical trial. In addition, his collaboration with Dr. Stephen Traynelis in Emory’s Department of Pharmacology and Chemical Biology led to the discovery of NP-10679. NP-10679 successfully wrapped up its Phase 1 clinical trial and has received Orphan Drug designation from the FDA for treating subarachnoid hemorrhage or bleeding in the space around the brain.
Dr. Liotta has helped transform HIV/AIDS from a death sentence to a chronic infection in which patients can live active and productive lives. The Emory University Office of Technology Transfer estimates that about 95% of the people living with HIV/AIDS in the U.S., and many around the world, take or have taken one of the drugs co-invented by Dr. Liotta. He is most noted for his invention of emtricitabine and lamivudine, along with Drs. Raymond Schinazi and Woo-Baeg Choi. These two drugs are widely used as crucial components of anti-HIV combination therapies. They played instrumental roles in combating the HIV/AIDS epidemic in the U.S. and curbing the spread of HIV in other regions of the world. Emtricitabine, marketed under the name Emtriva, made possible the first-ever combination therapy for HIV/AIDS as a once-daily pill. It is a component of many combination therapies used to treat HIV/AIDS. Lamivudine, marketed under the name Epivir, is also a component of multiple combination therapies. Additionally, lamivudine became the first drug approved by the FDA to treat hepatitis B infections. Both emtricitabine and lamivudine are on the World Health Organization’s List of Essential Medicines.
In addition to antiviral therapeutics, Dr. Liotta has also made important contributions to other therapeutic fronts, such as oncology and neurological diseases. He co-discovered samuraciclib (formerly CT7001), a CDK7 inhibitor for treating hard-to-treat cancers. Samuraciclib is in Phase 2 clinical trials and has been fast-tracked by the FDA for use in two combination therapies to treat certain breast cancers. He also developed Q-122, an oral drug for controlling hot flashes in postmenopausal women, which has completed a Phase 2 clinical trial. In addition, his collaboration with Dr. Stephen Traynelis in Emory’s Department of Pharmacology and Chemical Biology led to the discovery of NP-10679. NP-10679 successfully wrapped up its Phase 1 clinical trial and has received Orphan Drug designation from the FDA for treating subarachnoid hemorrhage or bleeding in the space around the brain.
研究兴趣
论文共 601 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Eric J. Miller, Petra Gregorova,Carrie Q. Sun,Leon Jacobs,Zafer Sahin,Yesim Altas Tahirovic,Samantha L. Burton, Priscilla Davidson, Hyungyu Lee, Yanli Yang, Nicholas Vugman,Rebecca S. Arnold,
ASPET 2024 Annual Meeting Abstract - Drug Discovery and Development (2024)
crossref(2023)
crossref(2023)
crossref(2023)
Leon Jacobs, Aletta van der Westhuyzen,Nicole Pribut,Zackery W Dentmon,Dan Cui,Michael P D'Erasmo,Perry W Bartsch,Ken Liu,Robert M Cox, Sujay F Greenlund,Richard K Plemper,Deborah Mitchell,
ACS medicinal chemistry lettersno. 10 (2023): 1434-1440
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCEno. 5 (2023): 702-709
Medicinal Chemistry Reviews 2023 Medicinal Chemistry Reviewspp.17-49, (2023)
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn